Evidence map›Paper›PMID 35035694›Full record

ArticleAmerican journal of translational research2021

Bromelain and acetylcysteine (BromAc

Ahmad H Mekkawy, Krishna Pillai, Hyerim Suh, Samina Badar, Javed Akhter, Vahan Képénékian, Kevin Ke, Sarah J Valle, David L Morris

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Safety of BromAcAmerican journal of cancer research · 2025
    Article
  3. Review
  4. Intraperitoneal BromAcCancers · 2023
    Article
  5. Bromelain and acetylcysteine (BromAcAmerican journal of cancer research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ahmad H MekkawyDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
Krishna PillaiDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
Hyerim SuhUniversity of New South Wales, St George & Sutherland Clinical School Sydney, NSW 2217, Australia.
Samina BadarDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
Javed AkhterDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
Vahan KépénékianMucpharm Pty Ltd Australia.
Kevin KeDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
Sarah J ValleDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
David L MorrisDepartment of Surgery, St. George Hospital Sydney, NSW 2217, Australia.
Starpharma (Australia) · AUSutherland Hospital · AUUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine (GEM) is commonly chosen for treating pancreatic cancer. However, its use is limited by toxicity. Earlier

Indexed as

acetylcysteineBromAc®bromelaingemcitabinein vitroin vivoPancreatic cancer

Identifiers

PMID35035694
PMCPMC8748110
OpenAlexW4206881746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.